Hypoactive Sexual Desire Disorder is a prevalent sexual function concern among women of all ages, from 7% of premenopausal women to 16% of surgically postmenopausal women. Sexual desire is influenced by physiological, psychological, and sociocultural aspects. In 2018 the International Society for the Study of Women's Sexual Health published guidelines for assessment and treatment of hypoactive sexual desire disorder outlining a biopsychosocial approach to this common concern. While we do not have a "female Viagra," there are now two FDA-approved medications for HSDD (Flibanserin and Bremelanotide). What is the rationale for these controversial medications? And why is there controversy?
Pebble Kranz, MD, FECSM is a family physician and sexual medicine specialist. She is medical director of the Rochester Center for Sexual Wellness and runs a sexual medicine clinic in the University of Rochester Medical Center’s Gynecologic Oncology Department. She has clinical appointments in the departments of family medicine and obstetrics and gynecology at University of Rochester. In 2018, she became a fellow of the European Committee on Sexual Medicine and is an active member of Sexual Medicine Society of North America, International Society for the Study of Women's Sexual Health, Scientific Network on Female Sexual Health and Cancer, and the American Association of Sexuality Educators, Counselors, and Therapists. At the Rochester Center for Sexual Wellness, she provides medical evaluations and treatments for sexual function concerns in people of all genders.
Click Here for Program Flyer